Published in final edited form as:

Appl Immunohistochem Mol Morphol. 2014 September ; 22(8): 593–599. doi:10.1097/PAI.0b013e3182a8d4bb.

Comparative evaluation of strategies for quantifying signaling pathway proteins in Ewing sarcoma

Mark A. Applebaum, MD¹, Dafydd G. Thomas, MD, PhD⁴, Todd Hembrough, PhD⁶, Jon Burrows, PhD⁶, Andrew E. Horvai, MD, PhD³, Elizabeth R. Lawlor, MD, PhD⁵, and Steven G. DuBois, MD²

¹Department of Pediatrics, University of Chicago, Chicago, Illinois

²Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, California

³Department of Pathology, University of California, San Francisco School of Medicine, San Francisco, California

⁴Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan

⁵Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan

⁶Department of OncoPlex Diagnostics, Rockville, MD

Keywords

Ewing sarcoma; immunohistochemistry; protein expression; mass spectrometry

Introduction

Ewing sarcoma (EWS) is an aggressive malignancy of bone and soft tissues with a peak incidence in adolescence. Outcomes for patients with localized disease have improved over the past 20 years, with approximately 70% of patients disease-free 5 years from initial diagnosis. In contrast, outcomes for patients with initially metastatic disease remain poor. Only 20-25% of these patients survive disease-free 5 years from initial diagnosis.^{1,2} Outcomes for patients with recurrent disease are also generally poor.³⁻⁵ As a result, targeted therapies are being increasingly evaluated in these populations.

The insulin-like growth factor type 1 (IGF-1), epithelial growth factor (EGF) and mTOR pathways have been shown to play important roles in the growth of EWS.⁶⁻⁹ Multiple preclinical models have shown EWS growth is inhibited by agents that interrupt these pathways by blocking IGF-1 receptor (IGF-1R) and mTOR.¹⁰⁻¹² Inhibition of epithelial

Corresponding Author: Steven DuBois, MD, Department of Pediatrics, UCSF School of Medicine, 505 Parnassus Avenue, M646, San Francisco, CA 94143-0106, Telephone: 415-476-3831, Facsimile: 415-502-4372, duboiss@peds.ucsf.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

growth factor receptor (EGFR) has been shown to be cytotoxic to EWS cells *in vitro* and increased EGFR expression may be one mechanism of resistance to IGF-1R inhibition.^{13,14} In the case of IGF-1R inhibitors, only a subset of patients has a clinical response, though with significant improvements in disease burden.^{15,16} Many groups have noted the need for improved use of biomarkers to identify patient subgroups who are most likely to respond to these targeted therapies.¹⁷⁻¹⁹ Furthermore, there is evidence that tumor expression of some growth signaling proteins is correlated to overall survival and thus quantified measurements of these proteins may be useful as prognostic biomarkers.²⁰ However, the optimal modality for quantifying expression of these proteins in the type of tumor material most commonly available for evaluation, formalin-fixed paraffin embedded tissue, has not been determined.

Several methods are available for quantifying clinically-relevant signaling pathway proteins in archival paraffin-embedded tumor material: standard immunohistochemistry (IHC); automated quantitative analysis (AQUA) immunohistochemistry;²¹ and mass spectrometry quantification.²² While standard immunohistochemistry is widely available, it is only semi-quantitative and cannot be multiplexed. AQUA immunohistochemistry and mass spectrometry have the benefit of being both fully quantitative and can be tested as a multiplex assay. However, neither assay has been compared to IHC for use with signaling proteins in EWS.

The primary aim of the current study was to compare the performance characteristics of these techniques in tissue from EWS patients in quantifying IGF-1R, EGFR, and mTOR signaling pathway proteins. A secondary aim was to track expression of these antigens over the disease course. The results could then be used to inform the adoption of new technologies for use in clinical trials of targeted agents for EWS and potentially other childhood cancers.

Materials and Methods

Patients

Tissue samples were obtained by evaluating the records of 129 patients with confirmed EWS who had been previously treated at the University of California, San Francisco. From the potential pool of 129 patients, our study population was limited to those patients who had open diagnostic biopsies or surgical resection of their tumor and excluded patient samples obtained by needle biopsy. Patients who underwent open biopsy or resection at the time of relapse were also included. The presence of viable tumor cells readily visible microscopically was also required for inclusion. These criteria were designed to ensure sufficient tumor material for analysis. 63 patients were screened based on available material. 46 blocks of formalin-fixed tissue with viable tumor were available from 40 patients of the original 63. 34 blocks of skeletal origin were decalcified using EDTA and dilute HCL (Decal Stat, Decal Chemical Corporation, Tallman, NY). 28 of the 46 samples were obtained at time of initial diagnosis, 11 after initial neoadjuvant chemotherapy during primary surgical excision and seven from patients with relapsed disease. The remaining 23 patients were excluded because of insufficient viable tumor, typically as a result of chemotherapy effect (n=18). Five patients had tissue blocks that could not be located. Six of the 40 patients had samples at both time of diagnosis and after initial therapy. Five of these

patients had tissue obtained after initial neoadjuvant chemotherapy and one after treatment relapse. One pathologist (AEH) reviewed all cases to confirm the diagnosis of EWS based on histology, immunohistochemistry, and/or cytogenetic/molecular data.

Study Overview

The initial study design included evaluation of protein expression of IGF-1R, phospho-IGF-1R, phospho-AKT, PTEN, EGFR, and phospho-P70S6 kinase. These proteins were chosen as they are involved in signaling pathways of potential interest for targeted therapy for EWS, including IGF-1R, EGFR, and mTOR pathways.

All samples were evaluated by standard immunohistochemistry and AQUA immunohistochemistry including six patients with samples from both diagnosis and after treatment. 25 samples were also selected for mass spectrometry analysis using tissue from 20 patients. Each of the selected patients had their diagnostic sample tested by mass spectrometry. Five of these patients had paired samples from a second time point, four after chemotherapy and one at time of relapse that were evaluated to better understand the changes in these biomarkers after treatment.

Sample Preparation and Evaluation

Tissue microarrays (TMAs) were prepared for both standard and AQUA immunohistochemistry. Positive and negative controls included normal liver, kidney and tonsil tissue.

Immunohistochemical staining was performed on the DAKO Autostainer (DAKO, Carpinteria, CA) using DAKO LSAB+ or polymerized detection system (Envision+, DAKO) and diaminobenzadine (DAB) as the chromogen as noted in Supplementary Table 1. Serial sections of de-paraffinized TMA sections were labeled with antibodies listed in Supplementary Table 1. Microwave citric acid epitope retrieval was used for all antibodies with the exception of EGFR. Appropriate negative (no primary antibody) and positive controls were stained in parallel with each set of tumors studied and yielded expected positive and negative staining

Protein expression by standard immunohistochemistry was evaluated using a 0-8 scale, 8 being the strongest staining using a modified Allred scoring schema.²³ Standard IHC results were also categorized as low (0-2), medium (3-5) and high (6-8). Samples were evaluated by a single pathologist (DT). Scoring was done blinded to results from AQUA or mass spectrometry to prevent bias.

Double immunofluorescence staining for AQUA was performed as previously described.²⁴ Briefly, after deparaffinization and rehydration, TMA slides were subjected to microwave epitope retrieval in 1 mM EDTA buffer, pH8. After rinsing several times in 10 mM Tris HCL buffer, pH 8 containing 0.154 M NaCl (TBS), endogenous peroxidase activity was blocked with 2.5% (v/v) H₂O₂ in methanol for 30 mins. Non-specific binding of the antibodies was extinguished by a 30 min incubation with 'Background Sniper' (BioCare Medical, Concord, CA). The TMA slide was then incubated with the tumor specific antibody, CD99 (species noted in Supplementary Table 2) overnight at 4C and each

antibody noted in Supplementary Table 2. Slides were then washed as described above and incubated with a combination of goat anti-mouse IgG conjugated to AF555 (Molecular probes, Carpinteria, CA, A21424, 1:200) in goat anti rabbit Envision+ (DAKO, Carpinteria, CA) or goat anti rabbit IgG conjugated to AF555 (Molecular Probes, Carpinteria, CA, A31630, 1:200) in goat anti mouse Envision+ (DAKO, Carpinteria, CA) for 60 minutes at room temperature in a dark humidity tray. The slides were then washed as described above and the target image is developed by a CSA reaction of Cy5 labeled tyramide (PerkinElmer, Waltham, MA, 1:50). The slides were washed with 3 changes of TBS and stained with the DNA staining dye 4',6-diaminodo-2-phenylindole (DAPI) in a non-fading mounting media (ProLong Gold, Molecular Probes, Carpinteria, CA). The slides were allowed to dry overnight in a dark dry chamber and the edges were sealed.

The AQUA system (HistoRx, New Haven, Connecticut) was used for the automated image acquisition and analysis. Briefly, images of each TMA core were captured with an Olympus BX51 microscope at 3 different extinction/emission wavelengths. Within each TMA spot, the area of tumor was distinguished from stromal and necrotic areas by creating a tumor specific mask from the anti-CD99 protein, which was visualized from Alexafluor 555 signal. The DAPI image was then used to differentiate between the cytoplasmic and nuclear staining within the tumor mask. Finally, the fluorescence pixel intensity of the protein/antibody complex was obtained from the Cy5 signal and reported as mean pixel intensity. Expression by AQUA was therefore measured as a continuous variable in arbitrary units.

For mass spectrometry analysis, 10 μ m unstained sections of each sample were prepared on proprietary Director slides (OncoPlex Diagnostics, Rockville, MD – formerly Expression Pathology, Inc.). Liquid Tissue lysates were prepared from these slides according to the manufacturer's recommendations (OncoPlex Diagnostics).²² Total protein content for each Liquid Tissue lysate was measured using a Micro BCA assay (Thermo Fisher Scientific Inc, Rockford, IL). Endogenous EGFR was quantitated using selected reaction monitoring (SRM)-MS by targeting the peptide IPLENLQIIR, which spans residues 98-108 of the EGFR extracellular domain. Likewise, IGF-1R was quantitated through the peptide GNLLINIR, which spans residues 358-365 of the protein's extracellular domain. A known amount of synthetic isotopically-labeled internal standard (5 fmol) for each peptide (IPLN[13C15N]LQIIR and GNL[13C15N]LINIR) was added to the samples. The sample (1 mg total) was analyzed using a nanoAcquityLC system (Waters, Milford, MA) coupled directly on-line with a TSQ Vantage triple quadrupole mass spectrometer (Thermo Scientific, San Jose, CA). The SRM-MS assays were acquired using the following mass spectrometer conditions: Q1(FWHM):0.2, Q2(FWHM):0.7, dwell time;10 ms. The precursor and product ions monitored for SRM-MS analysis of EGFR and IGF-1R have been reported previously.²² Each sample was analyzed in triplicate. PTEN was not included in the mass spectroscopy panel for technical reasons. The area under the curve (AUC) for the endogenous and isotopically-labeled standard peptide was used to calculate the absolute abundance of EGFR and IGF-1R in each sample. The concentration of endogenous SPARC peptide was calculated using the following formula:

$$\frac{\text{AUC endogenous peptide}}{\text{AUC isotopically-labeled peptide(internal standard)}} \times \frac{\text{amol isotopically-labeled peptide}^*}{\mu\text{g total protein}^{**}} = \text{amol endogenous peptide per } \mu\text{g}$$

*Quantity of spiked isotopically-labeled internal standard (amol) injected

**Quantity of total protein injected

Statistical Methods

Correlation coefficients were calculated by linear regression. One-sided ANOVA analysis was used to compare the mean AQUA expression for each analyte between categories of expression by IHC using single sample from each patient at the earliest time point in their disease. Two sided unpaired t-tests were used to compare means between groups at initial diagnosis and after initiation of chemotherapy. All statistical analyses were performed using STATA, version 11.

Results

Patient Characteristics

Samples were available from 40 patients whose characteristics can be seen in Table 1. The mean age of patients was 14 years (range 1-49 yrs) at time of diagnosis. 67.5% were male and 57.5% had localized disease. Overall survival for this cohort was 72.5% with a median follow up time of 51 months.

Protein Expression by Standard IHC, AQUA IHC and Mass Spectrometry

AQUA and standard immunohistochemistry were attempted for EGFR, IGF-1R, phospho-AKT, phospho-IGF-1R, phospho-70S6k and PTEN. Due to technical issues, results were only available for IGF-1R, EGFR and PTEN, an inhibitor of the Pi3K/AKT/mTOR pathway. One sample per patient was analyzed, with the sample from initial diagnosis included in the primary analysis if multiple samples were available in a given patient. Overall expression results can be seen in Table 2. Standard IHC yielded expression results in 35 of 46 samples for IGF-1R (76.1%), 36 samples for EGFR (78.3%) and 35 samples for PTEN (76.1%). AQUA yielded expression results in 34 of 46 samples for IGF-1R (73.9%), 37 samples for EGFR (80.4%) and 42 samples for PTEN (91.3%). A representative image for AQUA IGF-1R staining can be seen in Figure 1. Mass spectrometry yielded expression results in 7 of 25 samples (25%) for IGF-1R and 8 of 25 samples (32%) for EGFR. PTEN expression was not available using this methodology. To account for the possible loss of protein from decalcification, we compared samples from both skeletal and non-skeletal origin and saw similar ranges for all proteins and methodologies.

AQUA IHC Compared to Standard IHC

Mean IGF-1R expression by AQUA did not differ significantly between standard IHC expression categories (mean IGF-1R expression by AQUA for low IHC = 11,255, medium IHC = 11070, high IHC = 11023; $p = 0.98$) (Figure 2A). Mean PTEN expression by AQUA was higher in the medium and high IHC categories (mean PTEN expression by AQUA for

low IHC = 1229, medium IHC = 2715, high IHC = 2940; $p = 0.064$) (Figure 2B). Only two samples expressed EGFR by standard IHC (Figure 2C). These samples qualitatively had higher AQUA expression levels, but there were too few samples for a reliable determination of statistical significance.

Mass Spectrometry Compared to Standard IHC and AQUA IHC

Qualitatively, there appeared to be a trend towards higher mass spectrometry values correlating with higher standard IHC (Figure 3A) and AQUA (Figure 3B) expression, but there were too few samples with available mass spectrometry data to merit formal statistical analysis.

Protein Expression Levels over Time

In order to better understand the changes in these biomarkers after treatment, we compared six post-treatment samples, five after chemotherapy and one at time of relapse, to those obtained from the same patient at initial diagnosis by AQUA (Figure 4). Intra-patient variability in expression as detected by AQUA was minimal as levels after initiation of therapy were similar to those measured prior to treatment. There was also no difference in mean expression by AQUA for all diagnostic samples compared to those obtained after initiation of treatment for IGF-1R (10330 vs. 10947; $p = 0.55$), EGFR (2912 vs. 2238; $p = 0.4$) and PTEN (2317 vs. 2359; $p = 0.93$). These data suggest that individual tumors have similar expression levels of these three proteins over time when patients are treated with standard cytotoxic agents according to current therapeutic protocols and that chemotherapy does not change expression significantly in residual viable tumor.

Discussion

In this study, we demonstrated the feasibility of quantifying protein expression of IGF-1R, EGFR and PTEN in paraffin embedded tumor samples from patients with Ewing sarcoma. AQUA immunohistochemistry showed that tumors express these proteins across a wide range. Furthermore, although IGF-1R expression by AQUA was similar across a range of standard IHC expression categories, increased expression of PTEN and EGFR by AQUA showed a trend towards increased standard IHC expression.

In this initial descriptive study, it is not possible to determine if one approach should be favored over the other approaches as a tool for quantifying these pathways in Ewing sarcoma. Ultimately, a reliable quantitative method could be used for establishing relative expression values that are clinically significant. It is not known whether there are critical threshold levels of expression of these signaling proteins that correlate with clinical behavior of Ewing sarcoma. Our work lays the groundwork for future studies that seek to determine the clinical impact of expression of these proteins, particularly within the context of clinical trials of targeted therapies.

Importantly, there is not a gold standard to which the results of each assay could be compared. Therefore, other performance characteristics must drive selection of a particular assay for use in future testing. For example, the low success rate for mass spectrometry in this histology suggests that this platform may not be optimal for future study. AQUA may

be preferred over standard IHC as more objective and more quantitative, though it is important to note that correlation between these two approaches was poor for IGF-1R. These two methods are also capable of determining nuclear versus cytoplasmic protein expression levels and could be evaluated in future studies.²⁵

Similar to AQUA, mass spectrometry also demonstrated a wide range of protein expression of IGF-1R and EGFR across samples. Higher mass spectrometric values appeared to correspond to high levels of expression on standard IHC. Unfortunately, this technique was not able to determine protein expression for a majority of the tumor samples tested. However, the mass spectrometry technique does define a lower limit of sensitivity and it may be that the low success rate also represents clinically insignificant levels of detection in these samples. Given previous success with this technique in other tumor types using frozen tissue^{26,27}, it is possible that the formalin fixation and, in a subset of cases, decalcification, may have interfered with this approach. While the protein expression levels in our study using tissue from skeletal and extraskeletal sources appeared similar, more samples would be needed to confirm this finding.

Interestingly, we observed stable expression levels of IGF-1R, EGFR, and PTEN when evaluated at multiple time points in therapy for an individual patient. This result is noteworthy as many centers are utilizing core needle biopsies or fine-needle aspiration to render an initial diagnosis of Ewing sarcoma. Therefore, paraffin-embedded tumor material may be scarce at diagnosis, but more plentiful at the time of definitive surgical local control. If our results are validated by other groups and in larger study cohorts, it may be feasible to evaluate tumor material from later in the disease course to infer expression at initial diagnosis.

The objective response rate of 10-15% for IGF-1R monoclonal antibodies in the treatment of patients with relapsed Ewing sarcoma motivates studies to understand possible resistance pathways to IGF-1R and other tyrosine kinase inhibitors. This experience also highlights the need to consider the potential for combining inhibitors of multiple different signaling pathways with each other and with conventional chemotherapy.²⁸⁻³¹ While IGF-1R, EGFR, and mTOR are all potential drug targets, it is yet to be fully determined if inhibition of any of these pathways can be augmented by simultaneously targeting other pathways.^{32,33} The ability to quantify pathway components and establish clinically relevant levels will be important to determine how the expression of these proteins drive tumor growth, survival and drug sensitivity. Ultimately, finding the optimal targeted strategy for an individual patient may be informed by studies quantifying protein expression in that individual's tumor.

Prior studies have evaluated the clinical impact of some of these signaling proteins in Ewing sarcoma. The IGFBP-3:IGF-1 ratio has been correlated to younger age at time of diagnosis but this did not correlate to outcomes.³⁴ A separate study evaluating 45 paraffin-embedded samples showed higher standard IHC expression levels of p-mTOR and p27(KIP1) were significantly associated with improved outcome.²⁰ These levels were not compared to the upstream drug targets evaluated in our study. A different report showed that patients whose tumors only showed nuclear staining of IGF-1R had better overall survival in a group of patients treated with an IGF-1R inhibitor.²⁵ The extent to which more quantitative

approaches, such as AQUA, might improve upon the predictive ability of these markers remains to be established.

One limitation of our study was the pooling of data obtained from samples obtained before and after initiation of chemotherapy. The samples obtained after start of treatment are likely enriched for tumor cells that were not responsive to therapy and may have different biologic properties compared to those cells that were sensitive to chemotherapy. Data suggest that patients with poor chemotherapy induced necrosis, which are the specimens that likely had adequate post treatment tumor samples, have worse overall outcomes.³⁵ While our immunohistochemistry assays for phospho-AKT and phospho-P70S were not successful, other studies have been able to do so using formalin fixed paraffin embedded tissue from other tumor types.^{36,37} This may be due either to biologic differences of the tumor type and/or differences in laboratory techniques. In addition, our sample size and retrospective study design make it difficult to determine the true correlation between quantitative methods of expression and standard IHC. Larger prospective studies are needed to clarify the optimal approach for each protein of interest.

Based on our findings, we conclude that growth signaling pathway proteins in Ewing sarcoma can be measured in a quantitative fashion. The three assays evaluated each have advantages and disadvantages that need to be considered in choosing an assay for a particular indication. Larger samples and a defined gold standard for comparison will be needed to determine the optimal approach for quantifying signaling proteins in Ewing sarcoma. These methods can then be used to aid the development of targeted therapies and evaluated as potential biomarkers predictive of response.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Support: Supported by the Campini Foundation and NIH/NCI 1K23CA154530. The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

References

1. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. *The New England journal of medicine*. 2003; 348:694.10.1056/NEJMoa020890 [PubMed: 12594313]
2. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2000; 18:3108–3114. [PubMed: 10963639]
3. Bacci G, Ferrari S, Longhi A, et al. Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. *Ann Oncol*. 2003; 14:1654–9. [PubMed: 14581274]
4. Barker LM, Pendergrass TW, Sanders JE, et al. Survival after recurrence of Ewing's sarcoma family of tumors. *J Clin Oncol*. 2005; 23:4354–62. doi:JCO.2005.05.105[pil]10.1200/JCO.2005.05.105. [PubMed: 15781881]

5. Rodriguez-Galindo C, Billups CA, Kun LE, et al. Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. *Cancer*. 2002; 94:561–9.10.1002/cncr.10192 [PubMed: 11900241]
6. Yee D, Favoni RE, Lebovic GS, et al. Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. *J Clin Invest*. 1990; 86:1806–14.10.1172/JCI114910 [PubMed: 2174908]
7. Scotlandi K, Benini S, Nanni P, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. *Cancer Res*. 1998; 58:4127–31. [PubMed: 9751624]
8. Andersson MK, Aman P. Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib. *Cancer Cell Int*. 2008; 8:1. doi:1475-2867-8-1 [pii] 10.1186/1475-2867-8-1. [PubMed: 18177496]
9. Zenali MJ, Zhang PL, Bendel AE, et al. Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in Ewing family of tumors. *Ann Clin Lab Sci*. 2009; 39:160–6. doi:39/2/160 [pii]. [PubMed: 19429803]
10. Benini S, Manara MC, Baldini N, et al. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. *Clin Cancer Res*. 2001; 7:1790–7. [PubMed: 11410521]
11. Manara MC, Landuzzi L, Nanni P, et al. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma. *Clin Cancer Res*. 2007; 13:1322–30. doi: 13/4/1322 [pii] 10.1158/1078-0432.CCR-06-1518. [PubMed: 17317844]
12. Martins AS, Mackintosh C, Martin DH, et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. *Clin Cancer Res*. 2006; 12:3532–40. doi:12/11/3532 [pii] 10.1158/1078-0432.CCR-05-1778. [PubMed: 16740780]
13. Chernoguz A, Crawford K, Donovan E, et al. EGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing's sarcoma model. *J Surg Res*. 2012; 173:1–9. doi:S0022-4804(11)00421-5 [pii] 10.1016/j.jss.2011.04.041. [PubMed: 21658718]
14. Hendrickson AW, Haluska P. Resistance pathways relevant to insulin-like growth factor-1 receptor-targeted therapy. *Curr Opin Investig Drugs*. 2009; 10:1032–40.
15. Juergens H, Daw NC, Georger B, et al. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. *J Clin Oncol*. 2011; 29:4534–40. doi:JCO.2010.33.0670 [pii] 10.1200/JCO.2010.33.0670. [PubMed: 22025154]
16. Pappo AS, Patel SR, Crowley J, et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. *J Clin Oncol*. 2011; 29:4541–7. doi:JCO.2010.34.0000 [pii] 10.1200/JCO.2010.34.0000. [PubMed: 22025149]
17. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. *Nat Rev Cancer*. 2012; 12:159–69. doi:nrc3215 [pii]10.1038/nrc3215. [PubMed: 22337149]
18. Gao J, Chang YS, Jallal B, et al. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. *Cancer Res*. 2012; 72:3–12. doi:72/1/3 [pii] 10.1158/0008-5472.CAN-11-0550. [PubMed: 22215692]
19. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? *J Natl Cancer Inst*. 2012; 104:975–81. doi:djs258 [pii] 10.1093/jnci/djs258. [PubMed: 22761272]
20. Mora J, Rodriguez E, de Torres C, et al. Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome. *Pediatr Blood Cancer*. 2012; 58:532–8.10.1002/pbc.23348 [PubMed: 21994054]
21. Dolled-Filhart M, Gustavson M, Camp RL, et al. Automated analysis of tissue microarrays. *Methods Mol Biol*. 2010; 664:151–62.10.1007/978-1-60761-806-5_15 [PubMed: 20690061]
22. Hembrough T, Thyparambil S, Liao WL, et al. Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue. *Clin Proteomics*. 2012; 9:5. doi:1559-0275-9-5 [pii] 10.1186/1559-0275-9-5. [PubMed: 22554165]
23. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. *J Clin Oncol*. 1999; 17:1474–81. [PubMed: 10334533]

24. Cooper A, van Doorninck J, Ji L, et al. Ewing tumors that do not overexpress BMI-1 are a distinct molecular subclass with variant biology: a report from the Children's Oncology Group. *Clin Cancer Res.* 2011; 17:56–66. doi:1078-0432.CCR-10-1417 [pii] 10.1158/1078-0432.CCR-10-1417. [PubMed: 21047978]
25. Asmane I, Watkin E, Alberti L, et al. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. *Eur J Cancer.* 2012; 48:3027–35. doi:S0959-8049(12)00409-1 [pii] 10.1016/j.ejca.2012.05.009. [PubMed: 22682017]
26. Liao CC, Ward N, Marsh S, et al. Mass spectrometry protein expression profiles in colorectal cancer tissue associated with clinico-pathological features of disease. *BMC Cancer.* 2010; 10:410. doi:1471-2407-10-410 [pii] 10.1186/1471-2407-10-410. [PubMed: 20691062]
27. Shen J, Person MD, Zhu J, et al. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. *Cancer Res.* 2004; 64:9018–26. doi: 64/24/9018 [pii] 10.1158/0008-5472.CAN-04-3262. [PubMed: 15604267]
28. Tap WD, Demetri G, Barnette P, et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. *J Clin Oncol.* 2012; 30:1849–56. doi:JCO.2011.37.2359 [pii] 10.1200/JCO.2011.37.2359. [PubMed: 22508822]
29. Subbiah V, Kurzrock R. Ewing's sarcoma: overcoming the therapeutic plateau. *Discov Med.* 2012; 13:405–15. [PubMed: 22742646]
30. Ho AL, Schwartz GK. Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning? *J Clin Oncol.* 2011; 29:4581–3. doi:JCO.2011.38.2374 [pii] 10.1200/JCO.2011.38.2374. [PubMed: 22025158]
31. Naing A, LoRusso P, Fu S, et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. *Clin Cancer Res.* 2012; 18:2625–31. doi:1078-0432.CCR-12-0061 [pii] 10.1158/1078-0432.CCR-12-0061. [PubMed: 22465830]
32. Gorlick R, Janeway K, Lessnick S, et al. Children's oncology group's 2013 blueprint for research: Bone tumors. *Pediatr Blood Cancer.* 2012; 1002/pbc.24429
33. Ahmed AA, Sherman AK, Pawel BR. Expression of therapeutic targets in Ewing sarcoma family tumors. *Hum Pathol.* 2012; 43:1077–83. doi:S0046-8177(11)00371-6 [pii] 10.1016/j.humpath.2011.09.001. [PubMed: 22196127]
34. Borinstein SC, Barkauskas DA, Krailo M, et al. Investigation of the insulin-like growth factor-1 signaling pathway in localized Ewing sarcoma: A report from the children's oncology group. *Cancer.* 2011 doi:10.1002/cncr.26112.
35. Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology.* 2000; 18:4–11. [PubMed: 10623687]
36. Sozopoulos E, Litsiou H, Voutsinas G, et al. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece. *Endocr Pathol.* 2010; 21:90–100. doi:10.1007/s12022-010-9112-0 [PubMed: 20186503]
37. Rios-Moreno MJ, Jaramillo S, Diaz-Delgado M, et al. Differential activation of MAPK and PI3K/AKT/mTOR pathways and IGF1R expression in gastrointestinal stromal tumors. *Anticancer Res.* 2011; 31:3019–25. doi:31/9/3019 [pii]. [PubMed: 21868553]

Figure 1.
Representative image of AQUA staining for IGF-1R.

Figure 2. Expression of signaling pathway proteins measured by AQUA immunohistochemistry compared to standard immunohistochemistry for IGF-1R (A), PTEN (B), EGFR (C).

Figure 3. Expression of signaling pathway proteins measured by mass spectrometry compared to standard immunohistochemistry (A) and AQUA immunohistochemistry (B) for IGF-1R and EGFR.

Figure 4.

Expression of signaling pathway proteins measured by AQUA immunohistochemistry in matched patient samples before and after initiation of chemotherapy.

Table 1

Characteristics of 40 patients with Ewing sarcoma and available tissue for quantification of signaling proteins.

Characteristic	All Patients n = 40	Patients with Tissue Evaluated by Mass Spectrometry n = 20
Median age at diagnosis (Range)	14 years (1-49 years)	13 years (1-45 years)
Median age at tissue collection (Range)	18 years (1-49 years)	15 years (1-46 years)
Male	67.5%	75.0%
Race		
White	67.5%	60.0%
Hispanic	17.5%	30.0%
Asian	10.0%	10.0%
African American	5.0%	0.0%
Stage		
Localized	57.5%	65.0%
Metastatic	30.0%	25.0%
Unknown	12.5%	10.0%
Tissue Origin		
Skeletal	72.5%	75.0%
Extraskeletal	27.5%	25.0%
Year of Diagnosis		
1990-1999	37.5%	40.0%
2000-2010	62.5%	60.0%

Table 2

Expression levels of signaling pathway proteins in paraffin-embedded Ewing sarcoma samples using three different methodologies.

Method	IGF-1R	PTEN	EGFR
Standard IHC Median Score (Range)	6 (0-8)	7 (0-8)	0 (0-3)
AQUA IHC Mean (Range)	10702 (393 – 14424)	2250 (251 – 6557)	2750 (672 – 9798)
Mass Spectrometry Mean (amol/μg) (Range)	246 (174 – 471)	N/A	234 (60 – 1052)